(Q37974990)

26 August 2017

Treatment of systemic lupus erythematosus: new advances in targeted therapy (English)

1 reference

systemic lupus erythematosus

26 August 2017

0 references

author name string

Mindy S Lo

series ordinal

1

1 reference

PubMed ID

22236448

26 August 2017

George C Tsokos

series ordinal

2

1 reference

PubMed ID

22236448

26 August 2017

language of work or name

English

0 references

publication date

11 January 2012

1 reference

Annals of the New York Academy of Sciences

26 August 2017

1 reference

26 August 2017

1247

1 reference

26 August 2017

138-152

1 reference

Treatment for lupus, first in 50 years, offers modest benefits, hope to patients

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Molecular mechanisms of glucocorticoid action: what is important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mycophenolate mofetil: ten years' experience of a renal transplant unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Clinical pharmacology and pharmacogenetics of thiopurines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

New drugs for aggressive B-cell and T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

21 January 2018

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

TACI is mutant in common variable immunodeficiency and IgA deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Interleukin 6 gene polymorphisms are associated with systemic lupus erythematosus in Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The role of IL-23/IL-17 axis in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The effect of anti-CD40 ligand in immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Inducible costimulator is essential for collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Calcium signaling in systemic lupus erythematosus T cells: a treatment target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury lupus project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Demethylation of CD40LG on the inactive X in T cells from women with lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The cyclic AMP response element modulator regulates transcription of the TCR zeta-chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Complement in lupus nephritis: the good, the bad, and the unknown

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

Interleukin-6 promoter polymorphism −174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.06263.X

10.1111/J.1749-6632.2011.06263.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22236448